Table 2.

Prevalence of pulmonary hypertension during tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia (N = 112).

	CML-associated PH, N (%)	Heart failure-associated PH, N (%)
Phase
Chronic	11/110 (10.0)	2/110 (1.8)
Accelerated	1/2 (50.0)	0/2 (0.0)
Total	12/112 (10.7)	2/112 (1.8)
TKI treated at the time of TTE examined
Imatinib	3/40 (7.5)	2/40 (5.0)
First line	3/39 (7.7)	2/39 (5.1)
Second or higher line	0/1 (0.0)	0/1 (0.0)
Nilotinib	1/32 (3.1)	1/32 (3.1)
First line	0/18 (0.0)	0/18 (0.0)
Second or higher line	1/14 (7.1)	0/14 (0.0)
Dasatinib	8/37 (21.6)	0/37 (0.0)
First line	6/28 (21.4)	0/37 (0.0)
Second or higher line	2/9 (22.2)	0/37 (0.0)
Radotinib	0/2 (0.0)	0/2 (0.0)
First line	0/1 (0.0)	0/1 (0.0)
Second or higher line	0/1 (0.0)	0/1 (0.0)
Ponatinib	0/1 (0.0)	0/1 (0.0)
Year of TTE examined,
2003–2016	7/20 (35.0)	1/20 (5.0)
2017–2020	5/92 (5.4)	1/92 (1.1)

CML = chronic myeloid leukemia, PH = pulmonary hypertension, TKI = tyrosine kinase inhibitor, TTE = transthoracic echocardiography.